Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATISSE
NCT05742607Phase 2Recruiting
- Sponsor
- Innate Pharma
- Start
- Jun 2023
- Primary completion
- Jun 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of IPH5201 in non-small cell lung cancer (NSCLC), sponsored by Innate Pharma. Started Jun 2023; status: recruiting.
02
Drugs
IPH5201
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05742607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05742607.